 |
Drug Preparedness and Response
to Bioterrorism
To help prepare our country for
possible bioterrorism attacks, FDA is working with other federal agencies to
make sure adequate supplies of medicine and vaccines are available to the
American public. This web page provides links to the most current
information on drug therapy and vaccines, plus advice on purchasing and taking
medication.
Anthrax
Plague
Back to Top
Radiation Emergencies
- Calcium-DTPA and
Zinc-DTPA. The FDA announces conditions under which calcium-DTPA
(Ca-DTPA) and zinc-DTPA (Zn-DTPA) can be found to be
safe and effective for the treatment of internal contamination with
plutonium, americium, or curium to increase the rates of elimination
of these substances from the body.
(Posted 9/12/2003)
- Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies
Optional Format: PDF
(Issued 12/2001, Posted 12/10/2001)
FDA has released guidance on using potassium iodide to reduce the risk of thyroid cancer in children and adults in emergencies involving the release of radioactive iodine into the environment.
- Prussian Blue.
FDA announces conditions under which Prussian blue can be found safe and
effective for the treatment of internal contamination with radioactive
cesium, radioactive thallium, or non-radioactive thallium. (1/31/2003)
Back to Top
Chemical Agents
- Atropen (atropine autoinjector). FDA has approved new dosage forms
of the Atropen for use in children and adolescents
exposed to certain nerve agents or insecticides. The Atropen has been
approved since 1973 for use in adults. FDA
Talk Paper (Posted 6/20/2003)
- Pyridostigmine
bromide. FDA has approved pyridostigmine bromide to increase survival
after exposure to Soman "nerve gas" poisoning. The product is
approved for combat use by United States military personnel. (Posted
2/5/2003)
- Reactive Skin Decontamination Lotion (RSDL). FDA has cleared
for use by the U.S. military a liquid decontamination lotion intended to
remove or neutralize chemical warfare agents and T-2 fungal toxin from the
skin. FDA
News (Issued 3/28/2003)
Regulatory Information
for Counter-terrorism Drug Development
Back to Top
Pediatric Counter-Terrorism
Measures
Anthrax
Chemical Agents
- Atropen (atropine autoinjector). FDA has approved new dosage forms
of the Atropen for use in children and adolescents
exposed to certain nerve agents or insecticides. The Atropen has been
approved since 1973 for use in adults. FDA
Talk Paper (Posted 6/20/2003)
Radiation Emergencies
- The FDA announces conditions under which calcium-DTPA (Ca-DTPA) and
zinc-DTPA (Zn-DTPA) can be found to be
safe and effective for the treatment of internal contamination with
plutonium, americium, or curium to increase the rates of elimination
of these substances from the body. Calcium-DTPA
and Zinc-DTPA Information. (For pediatric information, please view the
labels.) (Posted 9/12/2003)
- Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies
Optional format: PDF
(Issued 12/2001, Posted 12/10/2001)
FDA has released guidance on using potassium iodide to reduce the risk of thyroid cancer in children and adults in emergencies involving the release of radioactive iodine into the environment.
-
Prussian Blue. FDA announces conditions under which Prussian blue can be found safe and
effective for the treatment of internal contamination with radioactive
cesium, radioactive thallium, or non-radioactive thallium. (1/31/2003)
- Prussian Blue: Approved Dosing
for Children
(draft labeling)
- FDA approves a New Drug Application for Radiogardase, also known as
Prussian blue, to treat people exposed to radiation contamination, due to
harmful levels of cesium-137 or thallium.
(Posted 10/2/2003)
Back to Top
Some files may require Adobe
Acrobat Reader.
 Back
to Top 
Back to Drug Information
Date created: October 31, 2001, updated October , 2008 |
|
